Psychedelic neurofeedback

Psychedelic neurofeedback, explained.

Psychedelic neurofeedback pairs a psychedelic session with brain training in the weeks around it. Here is what that means, why the timing matters, and how Psio does it.

What is neurofeedback?

Neurofeedback is a form of brain training. A sensor on the scalp reads brain activity, known as EEG, and an app gives feedback in real time, usually through sound or visuals, whenever the brain moves toward a target pattern. Over repeated sessions the brain learns to reach that pattern more easily, much like practicing any other skill. It has been used in clinical settings for decades.

Why pair it with psychedelics?

Psychedelics such as psilocybin and ketamine appear to open a temporary window when the brain is unusually able to change. In mice, a single dose of psilocybin increased the number of connections between neurons in the frontal cortex within a day, and the increase lasted at least a month [1]. Another study found that psychedelics reopened a period of heightened social learning in mice, which stayed open for about 48 hours after ketamine and about two weeks after psilocybin [2].

These are animal findings, and the details in people are still being studied. But they point to a simple idea: the weeks after a session are a window, and what happens in that window matters. Psychedelic neurofeedback is a way to use that window on purpose, with a short, measured practice instead of hoping the change holds on its own.

How Psio does it

Who it is for

Psio is built for clinics and facilitators who offer psilocybin or ketamine care and want to support clients in the weeks between and after sessions, without building a qEEG lab or hiring a technician. Individuals working with a provider can also start care with Psio directly.

Psio supports care alongside a client's provider. It is not a medical device and does not replace the guidance of a facilitator, therapist, or treatment team.

Get started with Psio

Clinics and facilitators can apply for early access. Individuals can start care now.

Not sure yet? Take the 2-minute assessment →
Devin Effinger, PhD

Psio was founded by Devin Effinger, PhD, a neuroscientist with a PhD in Neuropharmacology from UNC Chapel Hill and postdoctoral research on psilocybin and LSD at CU Anschutz.

Sources

  1. [1] Shao L-X, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron, 2021 (summary from Yale University). Source
  2. [2] Nardou R, et al. Psychedelics reopen the social reward learning critical period. Nature, 2023 (summary from Johns Hopkins Medicine). Source

Keep reading